Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.

Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys

Open access

Abstract

BACKGROUND: Antihypertensive medicines are effective in reducing adverse cardiovascular events. Our aim was to compare hypertension awareness, treatment, and control, and how they have changed over time, in high-income countries. METHODS: We used data from people aged 40-79 years who participated in 123 national health examination surveys from 1976 to 2017 in 12 high-income countries: Australia, Canada, Finland, Germany, Ireland, Italy, Japan, New Zealand, South Korea, Spain, the UK, and the USA. We calculated the proportion of participants with hypertension, which was defined as systolic blood pressure of 140 mm Hg or more, or diastolic blood pressure of 90 mm Hg or more, or being on pharmacological treatment for hypertension, who were aware of their condition, who were treated, and whose hypertension was controlled (ie, lower than 140/90 mm Hg). FINDINGS: Data from 526 336 participants were used in these analyses. In their most recent surveys, Canada, South Korea, Australia, and the UK had the lowest prevalence of hypertension, and Finland the highest. In the 1980s and early 1990s, treatment rates were at most 40% and control rates were less than 25% in most countries and age and sex groups. Over the time period assessed, hypertension awareness and treatment increased and control rate improved in all 12 countries, with South Korea and Germany experiencing the largest improvements. Most of the observed increase occurred in the 1990s and early-mid 2000s, having plateaued since in most countries. In their most recent surveys, Canada, Germany, South Korea, and the USA had the highest rates of awareness, treatment, and control, whereas Finland, Ireland, Japan, and Spain had the lowest. Even in the best performing countries, treatment coverage was at most 80% and control rates were less than 70%. INTERPRETATION: Hypertension awareness, treatment, and control have improved substantially in high-income countries since the 1980s and 1990s. However, control rates have plateaued in the past decade, at levels lower than those in high-quality hypertension programmes. There is substantial variation across countries in the rates of hypertension awareness, treatment, and control. FUNDING: Wellcome Trust and WHO.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(19)31145-6

Cites

37 of 37 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trends in hypertension prevalence by country, sex, and age group See appendix (pp 29–41) for country-by-country results. Error bars indicate 95% CIs.
Figure 1 Trends in hypertension prevalence by country, sex, and age group See appendix (pp 29–41) for country-by-country results. Error bars indicate 95% CIs.CC BY · PubMed Central
Figure 2 Prevalence of hypertension and rates of awareness, treatment, and control in women and men aged 40–79 years Data are from the latest national survey in each country. Results shown are crude (ie, not age-standardised) to reflect the total burden of hypertension and its awareness, treatment, and control. Age-specific results, and their uncertainty, are available in Figure 1, Figure 3, Figure 4, Figure 5, Figure 6, and the appendix (pp 7–9). For each outcome, the colour range for cells extends from lowest to highest value. Men and women share the same colour scheme. Awareness, treatment, and control are reported as the proportions. *The latest national survey in Ireland had data for people aged 50 to 79 years; data from an earlier survey in 2007 were used for people aged 40 to 49 years. †The question on awareness was not asked in 2015 in Japan; awareness data from 2010 were used. ‡The latest national survey in Spain had data for people aged 60 to 79 years; data from an earlier survey in 2009 were used for people aged 40 to 59 years.
Figure 2 Prevalence of hypertension and rates of awareness, treatment, and control in women and men aged 40–79 years Data are from the latest national survey in each country. Results shown are crude (ie, not age-standardised) to reflect the total burden of hypertension and its awareness, treatment, and control. Age-specific results, and their uncertainty, are available in Figure 1, Figure 3, Figure 4, Figure 5, Figure 6, and the appendix (pp 7–9). For each outcome, the colour range for cells extends from lowest to highest value. Men and women share the same colour scheme. Awareness, treatment, and control are reported as the proportions. *The latest national survey in Ireland had data for people aged 50 to 79 years; data from an earlier survey in 2007 were used for people aged 40 to 49 years. †The question on awareness was not asked in 2015 in Japan; awareness data from 2010 were used. ‡The latest national survey in Spain had data for people aged 60 to 79 years; data from an earlier survey in 2009 were used for people aged 40 to 59 years.CC BY · PubMed Central
Figure 3 Trends in hypertension awareness and treatment among people with hypertension, by country, sex, and age group See appendix (pp 29–41) for country-by-country results. Error bars indicate 95% CIs.
Figure 3 Trends in hypertension awareness and treatment among people with hypertension, by country, sex, and age group See appendix (pp 29–41) for country-by-country results. Error bars indicate 95% CIs.CC BY · PubMed Central
Figure 4 Age patterns of hypertension awareness, treatment, and control among women and men, according to the latest national surveys
Figure 4 Age patterns of hypertension awareness, treatment, and control among women and men, according to the latest national surveysCC BY · PubMed Central
Figure 5 Trends in proportion of people with hypertension who had undiagnosed or untreated stage 2 hypertension, by country, sex, and age group Error bars indicate 95% CIs.
Figure 5 Trends in proportion of people with hypertension who had undiagnosed or untreated stage 2 hypertension, by country, sex, and age group Error bars indicate 95% CIs.CC BY · PubMed Central
Figure 6 Trends in hypertension control, by country, sex, and age group See appendix (pp 29–41) for country-by-country results. Error bars indicate 95% CIs.
Figure 6 Trends in hypertension control, by country, sex, and age group See appendix (pp 29–41) for country-by-country results. Error bars indicate 95% CIs.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 37 references

Research works printed but not linked: 1

  1. Whelton, 2018, Hypertension, 71, e13

Cited by

See all 544

Metadata

Authors
Zhou, B., Danaei, G., Stevens, G. A., Bixby, H., Taddei, C., Carrillo-Larco, R. M., Solomon, B., Riley, L. M., Di Cesare, M., Iurilli, M. L. C., Rodriguez-Martinez, A., Zhu, A., Hajifathalian, K., Amuzu, A., Banegas, J. R., Bennett, J. E., Cameron, C., Cho, Y., Clarke, J., Craig, C. L., Cruz, J. J., Gates, L., Giampaoli, S., Gregg, E. W., Hardy, R., Hayes, A. J., Ikeda, N., Jackson, R. T., Jennings, G., Joffres, M., Khang, Y.-H., Koskinen, S., Kuh, D., Kujala, U. M., Laatikainen, T., Lehtimäki, T., Lopez-Garcia, E., Lundqvist, A., Maggi, S., Magliano, D. J., Mann, J. I., McLean, R. M., McLean, S. B., Miller, J. C., Morgan, K., Neuhauser, H. K., Niiranen, T. J., Noale, M., Oh, K., Palmieri, L., Panza, F., Parnell, W. R., Peltonen, M., Raitakari, O., Rodríguez-Artalejo, F., Roy, J. G., Salomaa, V., Sarganas, G., Servais, J., Shaw, J. E., Shibuya, K., Solfrizzi, V., Stavreski, B., Tan, E. J., Turley, M. L., Vanuzzo, D., Viikari-Juntura, E., Weerasekera, D., & Ezzati, M.
Affiliations
Imperial College London (GB)
Corresponding author
Ezzati, Majid
Venue
The Lancet
Publisher
Elsevier BV
Published
2019-08
Volume
394
Issue
10199
Pages
639-651
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2961144637
Cited by
544
References
37
Citations by year
2026: 53 · 2025: 72 · 2024: 75 · 2023: 84 · 2022: 63 · 2021: 104 · 2020: 84 · 2019: 9
FWCI
11.78
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (publishedVersion)
  • St George's Online Research Archive (St George's University of London) (acceptedVersion)
  • Middlesex University Research Repository (Middlesex University Of London) (submittedVersion)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by)
  • Jyväskylä University Digital Archive (University of Jyväskylä) (submittedVersion, cc-by)
  • Biblos-e Archivo (Universidad Autónoma de Madrid) (submittedVersion, public-domain)
  • UTUPub (University of Turku) (submittedVersion)
  • UCL Discovery (University College London) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • Hispana (submittedVersion)
  • Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, other-oa)
  • Seoul National University Open Repository (Seoul National University) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion, other-oa)
  • Tampere University Institutional Repository (Tampere University) (submittedVersion, cc-by)
  • STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
  • Lenus, The Irish Health Repository (Dr Steevens Hospital Library) (submittedVersion, cc-by)
Funders
  • Eli Lilly and Company
  • Pfizer
  • AstraZeneca
  • GlaxoSmithKline
  • Sanofi
  • Foundation for Cardiovascular Research
  • Wellcome Trust (214185/Z/18/Z)
  • Health Research Board (TILDA-2017-1)
  • Diabetes Australia
  • Kidney Health Australia
  • Ministry of Health, New Zealand
  • Ministry of Education, Culture, Sports, Science and Technology
  • Ministry of Health, Labour and Welfare
  • Novo Nordisk
  • Sydäntutkimussäätiö
  • Servier
  • Japan Society for the Promotion of Science (18H03063)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Nursing › Nutrition and Dietetics › Sodium Intake and Health
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health Promotion and Cardiovascular Prevention
Keywords
hypertension, hypertension awareness, antihypertensive therapy, blood pressure control, antihypertensive drugs, hypertension prevalence, temporal trends, country variation, high-income countries, cardiovascular disease prevention
MeSH terms
Adult, Aged, Antihypertensive Agents, Blood Pressure, Female, Health Surveys, Humans, Hypertension, Health Knowledge, Attitudes, Practice, Male, Middle Aged, Prevalence, Age Distribution, Sex Distribution, Developed Countries

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. https://app.cochat.ai/papers/10.1016/s0140-6736(19)31145-6
The paper
Zhou, B., Danaei, G., Stevens, G. A., Bixby, H., Taddei, C., Carrillo-Larco, R. M., Solomon, B., Riley, L. M., Di Cesare, M., Iurilli, M. L. C., Rodriguez-Martinez, A., Zhu, A., Hajifathalian, K., Amuzu, A., Banegas, J. R., Bennett, J. E., Cameron, C., Cho, Y., Clarke, J., . . . Ezzati, M. (2019). Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. The Lancet. https://doi.org/10.1016/s0140-6736(19)31145-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.